Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab-IRDye800CW in HNSCC
NCT07460765Phase 1Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jul 2026
- Primary completion
- Apr 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Nivolumab-IRDye800CW in head and neck squamous cell carcinoma (HNSCC) (4 cohorts), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Occurrence of clinically significant Grade >=2 adverse events. Started Jul 2026; status: recruiting.
02
Drugs
Nivolumab-IRDye800CW
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07460765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07460765.